JP2007509978A5 - - Google Patents

Download PDF

Info

Publication number
JP2007509978A5
JP2007509978A5 JP2006538354A JP2006538354A JP2007509978A5 JP 2007509978 A5 JP2007509978 A5 JP 2007509978A5 JP 2006538354 A JP2006538354 A JP 2006538354A JP 2006538354 A JP2006538354 A JP 2006538354A JP 2007509978 A5 JP2007509978 A5 JP 2007509978A5
Authority
JP
Japan
Prior art keywords
moiety
compound
therapeutic drug
composition
tocopherol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006538354A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007509978A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/036127 external-priority patent/WO2005042539A1/en
Publication of JP2007509978A publication Critical patent/JP2007509978A/ja
Publication of JP2007509978A5 publication Critical patent/JP2007509978A5/ja
Pending legal-status Critical Current

Links

JP2006538354A 2003-10-29 2004-10-29 トコフェロール修飾治療薬化合物 Pending JP2007509978A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US51536403P 2003-10-29 2003-10-29
US55613704P 2004-03-24 2004-03-24
US55876204P 2004-04-01 2004-04-01
US62165504P 2004-10-26 2004-10-26
PCT/US2004/036127 WO2005042539A1 (en) 2003-10-29 2004-10-29 Tocopherol-modified therapeutic drug compounds

Publications (2)

Publication Number Publication Date
JP2007509978A JP2007509978A (ja) 2007-04-19
JP2007509978A5 true JP2007509978A5 (enExample) 2007-12-13

Family

ID=34557676

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006538354A Pending JP2007509978A (ja) 2003-10-29 2004-10-29 トコフェロール修飾治療薬化合物

Country Status (12)

Country Link
US (3) US7223770B2 (enExample)
EP (1) EP1682552B1 (enExample)
JP (1) JP2007509978A (enExample)
KR (1) KR20060110872A (enExample)
AT (1) ATE472551T1 (enExample)
AU (1) AU2004285037B2 (enExample)
BR (1) BRPI0415858A (enExample)
CA (1) CA2543722C (enExample)
DE (1) DE602004027936D1 (enExample)
IL (1) IL175158A0 (enExample)
TW (1) TW200522978A (enExample)
WO (1) WO2005042539A1 (enExample)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8557861B2 (en) * 2004-09-28 2013-10-15 Mast Therapeutics, Inc. Low oil emulsion compositions for delivering taxoids and other insoluble drugs
KR100848919B1 (ko) * 2004-11-05 2008-07-29 주식회사 삼양사 10-히드록시캄토테신 화합물의 극성 비수성 용매에 대한용해도를 증가시키기 위한 약제학적 제형
GT200500310A (es) 2004-11-19 2006-06-19 Compuestos organicos
WO2006089290A1 (en) 2005-02-18 2006-08-24 Abraxis Bioscience Inc.. Combinations and modes of administration of therapeutic agents and combination therapy
SA06270147B1 (ar) 2005-06-09 2009-12-22 نوفارتيس ايه جي عملية لتخليق 5-(مثيل–1h–إيميدازول–1-يل )–3-(ثلاثي فلـورو مثيل)–بنزامـين
KR20130079645A (ko) 2005-07-18 2013-07-10 유니버시티 오브 메사츄세츠 로웰 나노에멀젼 조성물 및 이의 제조 및 사용 방법
AU2016244292A1 (en) * 2005-07-18 2016-11-03 University Of Massachusetts Lowell Compositions and methods for making and using nanoemulsions
US20090306198A1 (en) * 2005-09-16 2009-12-10 Robert Nicolosi Anti-Oxidant Synergy Formulation Nanoemulsions to Treat Caner
US7727514B2 (en) * 2005-10-03 2010-06-01 Biotechnology Research & Development Corporation Compositions comprising a UV-absorbing chromophore
US7744856B2 (en) * 2005-10-03 2010-06-29 Biotech Research And Development Corporation Formulations with feruloyl glycerides and methods of preparation
US7572610B2 (en) * 2005-10-03 2009-08-11 Biotechnology Research & Development Corporation Methods of making compositions comprising a UV-Absorbing chromophore
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
CN101374498A (zh) 2005-12-01 2009-02-25 麻萨诸塞州洛厄尔大学 肉毒杆菌纳米乳液
WO2007075492A1 (en) * 2005-12-16 2007-07-05 Sonus Pharmaceuticals, Inc. Lipophilic anticancer drug compounds
CZ300305B6 (cs) * 2005-12-20 2009-04-15 Heaton, A. S. Farmaceutická kompozice obsahující derivát taxanu se zlepšenou terapeutickou úcinností
US20070167422A1 (en) * 2006-01-18 2007-07-19 Yu Kwok S Pharmaceutical compositions comprising 17-allylamino-17-demethoxygeldanamycin
TWI376239B (en) * 2006-02-01 2012-11-11 Andrew Xian Chen Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof
BRPI0713966A2 (pt) * 2006-06-29 2012-11-27 Biotech Res And Dev Corp formulações com feruloil glicerìdeos e métodos de preparação
WO2008016664A2 (en) * 2006-08-02 2008-02-07 University Of Massachusetts Lowell Compositions and methods for treating cancer with dacarbazine nanoemulsions
SG10201607909WA (en) * 2006-12-01 2016-11-29 Anterios Inc Peptide nanoparticles and uses therefor
WO2008070538A2 (en) 2006-12-01 2008-06-12 Anterios, Inc. Micellar nanoparticles comprising botulinum toxin
CN101765423B (zh) 2007-05-31 2014-08-06 安特里奥公司 核酸纳米粒子和其用途
JP2010530872A (ja) * 2007-06-22 2010-09-16 サイドース・エルエルシー Tween80を含まないドセタキセル可溶化製剤
CN101878024B (zh) * 2007-11-28 2014-04-09 塞拉特药物股份有限公司 改良的紫杉烷递送系统
MX2010010214A (es) 2008-03-20 2010-12-21 Virun Inc Derivados de vitamina e y sus usos.
EP2548456B1 (en) 2008-03-20 2015-07-08 Virun, Inc. Emulsions including a PEG-derivative of tocopherol
US7670894B2 (en) * 2008-04-30 2010-03-02 Intel Corporation Selective high-k dielectric film deposition for semiconductor device
KR102080429B1 (ko) * 2008-06-26 2020-02-21 안테리오스, 인코퍼레이티드 경피 운반
WO2010124223A1 (en) * 2009-04-23 2010-10-28 First Tech International Limited Anti-cancer tocotrienol analogues and associated methods
US9180113B2 (en) * 2009-09-01 2015-11-10 First Tech International Limited Tocotrienol compositions
US7772274B1 (en) 2009-10-19 2010-08-10 Scidose, Llc Docetaxel formulations with lipoic acid
US8912228B2 (en) 2009-10-19 2014-12-16 Scidose Llc Docetaxel formulations with lipoic acid
US8541465B2 (en) * 2009-10-19 2013-09-24 Scidose, Llc Docetaxel formulations with lipoic acid and/or dihydrolipoic acid
US20110092579A1 (en) * 2009-10-19 2011-04-21 Scidose Llc Solubilized formulation of docetaxel
WO2011097481A1 (en) * 2010-02-05 2011-08-11 First Tech International Limited Tocotrienol esters
WO2011103512A1 (en) * 2010-02-18 2011-08-25 Martek Biosciences Corporation Dha free fatty acid emulsions
CA2792330C (en) * 2010-03-23 2017-01-03 Virun, Inc Nanoemulsion including a peg-derivative of vitamin e and a sucrose fatty acid ester
WO2011123393A1 (en) 2010-03-29 2011-10-06 Abraxis Bioscience, Llc Methods of enhancing drug delivery and effectiveness of therapeutic agents
NZ602385A (en) 2010-03-29 2014-08-29 Abraxis Bioscience Llc Methods of treating cancer
KR20130088116A (ko) 2010-06-04 2013-08-07 아브락시스 바이오사이언스, 엘엘씨 췌장암의 치료 방법
US8741373B2 (en) 2010-06-21 2014-06-03 Virun, Inc. Compositions containing non-polar compounds
JP5892658B2 (ja) 2010-08-20 2016-03-23 国立大学法人 東京医科歯科大学 経大腸吸収用医薬組成物
US20120178813A1 (en) 2011-01-12 2012-07-12 Thetis Pharmaceuticals Llc Lipid-lowering antidiabetic agent
CN102516258B (zh) * 2011-11-11 2014-06-25 正大天晴药业集团股份有限公司 水溶性维生素e衍生物修饰的脂溶性抗癌药物化合物和制剂、该化合物的制备方法及应用
CA2863544C (en) 2012-02-10 2019-03-26 Virun, Inc. Beverage compositions containing non-polar compounds
CN102731519B (zh) * 2012-06-26 2014-12-17 济南精合医药科技有限公司 用于抗肿瘤药物的对硝基芳甲氧基喜树碱缺氧激活前药
CN102731518B (zh) * 2012-06-26 2014-12-03 济南精合医药科技有限公司 用于抗肿瘤药物的邻硝基芳甲氧基喜树碱缺氧激活前药
US9382187B2 (en) 2012-07-10 2016-07-05 Thetis Pharmaceuticals Llc Tri-salt form of metformin
US8765811B2 (en) 2012-07-10 2014-07-01 Thetis Pharmaceuticals Llc Tri-salt form of metformin
US9351517B2 (en) 2013-03-15 2016-05-31 Virun, Inc. Formulations of water-soluble derivatives of vitamin E and compositions containing same
US20140314672A1 (en) * 2013-04-06 2014-10-23 Igdrasol, Inc. Nanoparticle therapeutic agents, their formulations, and methods of their use
US20150147382A1 (en) * 2013-09-23 2015-05-28 Exir Nano Sina Company Topical liposomal compositions for delivering hydrophobic drugs and methods preparing same
US9505709B2 (en) 2014-05-05 2016-11-29 Thetis Pharmaceuticals Llc Compositions and methods relating to ionic salts of peptides
WO2015171924A2 (en) * 2014-05-07 2015-11-12 Cornell University Inhibitors of fusion between viral and cell membranes as well as compositions and methods of using them
KR20170023061A (ko) 2014-06-18 2017-03-02 테티스 파마수티컬스 엘엘씨 활성제의 미네랄 아미노산 복합체
US9242008B2 (en) 2014-06-18 2016-01-26 Thetis Pharmaceuticals Llc Mineral amino-acid complexes of fatty acids
US9861611B2 (en) 2014-09-18 2018-01-09 Virun, Inc. Formulations of water-soluble derivatives of vitamin E and soft gel compositions, concentrates and powders containing same
WO2016057825A1 (en) * 2014-10-08 2016-04-14 Epigenetics Pharma Llc Vitamin e-nucleoside prodrugs
CN105777770B (zh) * 2014-12-26 2018-05-25 中国人民解放军第二军医大学 一种饱和长链脂肪酸修饰的7-乙基-10-羟基喜树碱化合物及其长循环脂质体
CN104800858B (zh) * 2015-04-27 2017-11-21 中国医学科学院基础医学研究所 Hsp90抑制肽偶联物及其在肿瘤治疗中的应用
GB2550346B (en) * 2016-05-13 2021-02-24 Phytoceutical Ltd Micelles
CA3026264A1 (en) 2016-06-03 2017-12-07 Thetis Pharmaceuticals Llc Compositions and methods relating to salts of specialized pro-resolving mediators
EP3510161A4 (en) 2016-08-23 2020-04-22 Akouos, Inc. COMPOSITIONS AND METHODS FOR TREATING PERSONAL HEARING LOSS IN A PERSON
EP3541358A1 (en) 2016-11-21 2019-09-25 Eirion Therapeutics, Inc. Transdermal delivery of large agents
US20200131231A1 (en) 2017-02-17 2020-04-30 Oxford University Innovation Limited Cell penetrating peptides
GB201812980D0 (en) 2018-08-09 2018-09-26 Univ Oxford Innovation Ltd Cell-penetrating peptides
GB201812972D0 (en) 2018-08-09 2018-09-26 Univ Oxford Innovation Ltd Cell-penetrating peptides
MX2021003116A (es) * 2018-09-17 2021-05-14 Childrens Hospital Philadelphia Profarmacos macromoleculares a base de polimero.
US12465646B2 (en) * 2018-12-07 2025-11-11 Oxford University Innovation Limited Linkers
CN116096905A (zh) 2020-02-21 2023-05-09 阿库斯股份有限公司 用于治疗人受试者的非年龄相关性听力损伤的组合物和方法
AU2022339721B2 (en) * 2021-09-05 2025-02-27 Tairx, Inc. Formulations with enhanced sn-38 solubility and oral absorption
MX2024003496A (es) 2021-10-15 2024-04-05 Kunshan Xinyunda Biotech Co Ltd Composicion que contiene un farmaco antitumoral, metodo de preparacion y uso de este.

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1395994A (en) 1972-08-23 1975-05-29 Delmar Chem Tocopherol derivative processes for making it and pharmaceutical compositions containing it
GB1409612A (en) 1973-09-13 1975-10-08 Ahrens G W Phenylpropyl-d-alpha-tocopherol-succinate the method for making the same and preparations
JPS5484034A (en) * 1977-12-16 1979-07-04 Nisshin Flour Milling Co Ltd Anti-tumor agent
EP0008573A1 (en) 1977-12-16 1980-03-05 Nisshin Flour Milling Co., Ltd. Anti-tumor agent
US4665204A (en) * 1985-06-27 1987-05-12 Henkel Corporation Diester derivatives of tocopherol
US5610180A (en) * 1988-01-29 1997-03-11 Virginia Commonwealth University Ionizable congeners of aromatic and aliphatic alcohols as anti-leukemia agents
US5234695A (en) * 1990-07-24 1993-08-10 Eastman Kodak Company Water dispersible vitamin E composition
DE59409377D1 (de) 1993-10-22 2000-06-29 Hexal Ag Pharmazeutische zusammensetzung mit cyclosporin a, einen vitamin e derivat und einen emulgator
GB9409778D0 (en) 1994-05-16 1994-07-06 Dumex Ltd As Compositions
CA2148148A1 (en) * 1994-05-20 1995-11-21 Kazumi Ogata Tocopherol derivatives
DE4423915A1 (de) 1994-07-07 1996-01-11 Carl Heinrich Dr Weischer Derivate des Salazosulfapyridins, deren Herstellung und Verwendung als Arzneimittel
US5858398A (en) * 1994-11-03 1999-01-12 Isomed Inc. Microparticular pharmaceutical compositions
US5945409A (en) * 1995-03-10 1999-08-31 Wilson T. Crandall Topical moisturizing composition and method
US5912078A (en) * 1996-05-02 1999-06-15 Milliken & Company Lubricant finish for textiles
US5919815A (en) 1996-05-22 1999-07-06 Neuromedica, Inc. Taxane compounds and compositions
US6576636B2 (en) * 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
JP4172726B2 (ja) * 1996-05-22 2008-10-29 ルイトポルド・ファーマシューティカルズ・インコーポレーテッド シス―ドコサヘキサエン酸とドセタキセルとの共有複合体を含有する製剤
US6258823B1 (en) * 1996-07-12 2001-07-10 Ariad Pharmaceuticals, Inc. Materials and method for treating or preventing pathogenic fungal infection
US5891469A (en) * 1997-04-02 1999-04-06 Pharmos Corporation Solid Coprecipitates for enhanced bioavailability of lipophilic substances
US6458373B1 (en) * 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US6727280B2 (en) * 1997-01-07 2004-04-27 Sonus Pharmaceuticals, Inc. Method for treating colorectal carcinoma using a taxane/tocopherol formulation
GB9715759D0 (en) * 1997-07-26 1997-10-01 Danbiosyst Uk New emulsion formulations
WO1999025729A1 (fr) * 1997-11-18 1999-05-27 Chugai Seiyaku Kabushiki Kaisha Composes possedant une activite antitumorale
US5917060A (en) * 1997-12-17 1999-06-29 Basf Aktiengesellschaft Preparation of chromanyl derivatives
JP4346239B2 (ja) * 1997-12-24 2009-10-21 千寿製薬株式会社 ビタミンe誘導体
US6086915A (en) * 1998-04-01 2000-07-11 Bioresponse L.L.C. Compositions and methods of adjusting steroid hormone metabolism through phytochemicals
RU2232758C2 (ru) * 1998-09-23 2004-07-20 Рисерч Дивелопмент Фаундейшн Токоферолы, токотриенолы и другие производные хромана и боковых цепей и способы лечения с их использованием
US6045826A (en) * 1999-04-02 2000-04-04 National Research Council Of Canada Water-soluble compositions of bioactive lipophilic compounds
WO2000071163A1 (en) * 1999-05-24 2000-11-30 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
WO2000077085A1 (en) * 1999-06-11 2000-12-21 Sydney Hyman Image making medium
JP2003513019A (ja) * 1999-09-27 2003-04-08 ソーナス ファーマシューティカルス,インコーポレイテッド トコール可溶性治療剤の組成物
US6136846A (en) * 1999-10-25 2000-10-24 Supergen, Inc. Formulation for paclitaxel
WO2002076970A2 (en) * 2001-03-23 2002-10-03 Sonus Pharmaceuticals, Inc. Tocopherol succinate derivatives and compositions
US6774116B2 (en) * 2001-04-17 2004-08-10 Cryolife, Inc. Prodrugs via acylation with cinnamate
US6858227B1 (en) * 2001-11-21 2005-02-22 Sonus Pharmaceuticals, Inc. Vitamin E conjugates
US6683194B2 (en) * 2002-02-05 2004-01-27 Sonus Pharmaceuticals, Inc. Tocopherol derivatives

Similar Documents

Publication Publication Date Title
JP2013503174A5 (enExample)
Beckers et al. Natural, semisynthetic and synthetic microtubule inhibitors for cancer therapy
CA2543722A1 (en) Tocopherol-modified therapeutic drug compounds
Hao et al. Micelles of d-α-tocopheryl polyethylene glycol 2000 succinate (TPGS 2K) for doxorubicin delivery with reversal of multidrug resistance
JP2022553857A5 (enExample)
JP2015501833A5 (enExample)
Rivera et al. Clinical development of ixabepilone and other epothilones in patients with advanced solid tumors
Lu et al. Hyaluronic acid-coated, prodrug-based nanostructured lipid carriers for enhanced pancreatic cancer therapy
JP2014511840A5 (enExample)
CN103044437A (zh) 用于治疗肿瘤的两亲性缀合物纳米颗粒及制备方法、应用
Wang et al. Design, synthesis and antineoplastic activity of novel hybrids of podophyllotoxin and indirubin against human leukaemia cancer cells as multifunctional anti-MDR agents
JP2005506298A5 (enExample)
CN1950376A (zh) 莪术醇衍生物、含该衍生物的组合物及所述衍生物的制药用途
JP2012506443A5 (enExample)
EP1480643A1 (en) Use of epothilones in the treatment of brain diseases associated with proliferative processes
AR040126A1 (es) Compuesto de fenilsulfonilo, composicion farmaceutica que lo comprende y su uso para la elaboracion de un medicamento
JP2011517455A5 (enExample)
Ferlini et al. New taxanes in development
HRP20140215T1 (hr) Kombinacija koja sadrži paklitaksel za lijeäśenje raka jajnika
JP2013518032A5 (enExample)
Zhou et al. EM012, a microtubule-interfering agent, inhibits the progression of multidrug-resistant human ovarian cancer both in cultured cells and in athymic nude mice
Siddiqui-Jain et al. Pharmacology and in vivo efficacy of pyridine-pyrimidine amides that inhibit microtubule polymerization
JP2004509919A (ja) 抗有糸分裂剤及び抗腫瘍剤としてのタキソイド接合体
Ma et al. Modulation of taxane binding to tubulin curved and straight conformations by systematic 3′ N modification provides for improved microtubule binding, persistent cytotoxicity and in vivo potency
RU2010140611A (ru) Комбинированное применение производных холестанола